CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tensha Therapeutics announced today it has begun the first clinical trial of its small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor, TEN-010 for the treatment of cancer. The trial is designed to assess the safety, tolerability and anti-tumor activity of TEN-010 in patients with advanced solid tumors that are refractory or intolerant to standard/approved therapies and NUT midline carcinoma (NMC), a highly aggressive cancer with very limited treatment options.
Help employers find you! Check out all the jobs and post your resume.
